Welcome to our dedicated news page for Heart Test Laboratories (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on Heart Test Laboratories .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heart Test Laboratories 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heart Test Laboratories 's position in the market.
Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has been granted a fundamental patent by the European Patent Office for assessing diastolic function of the heart using AI-ECG. Diastolic dysfunction is important for early detection of heart disease, preceding symptoms. The patent covers the use of AI-ECG for any echo measure of diastolic function, making it a valuable tool for heart screening in clinical settings. This patent reinforces HeartSciences' position in AI-ECG technology and is expected to drive significant growth in the ECG market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.1%
Tags
-
Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, announced CEO Andrew Simpson's presentation at the LD Micro Invitational XIV Conference. The focus is on transforming ECGs/EKGs for early heart disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
HeartSciences (NASDAQ: HSCS) presented a study showcasing the effectiveness of MyoVista wavECG in screening preoperative patients for LVDD at the 18th World Congress of Anesthesiologists. The study demonstrated 100% sensitivity in detecting LVDD, potentially reducing unnecessary referrals to echocardiography. MyoVista wavECG shows promise in transforming cardiovascular medicine and is set to be commercially available soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
Rhea-AI Summary
HeartSciences, a medical technology company, reported Q3 FY2024 financial results showing a strengthened financial position, strategic shifts, and business highlights. Key accomplishments include acquiring AI-ECG algorithms from Mount Sinai, FDA pathway changes, and enhanced team recruitment. The company aims to lead the AI-ECG market with improved financials, extended cash runway, and clinical advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
Rhea-AI Summary
HeartSciences (NASDAQ: HSCS) announces a study showing MyoVista AI-ECG model outperforms NT-proBNP and ARIC HF score in Stage B Heart Failure screening among type 2 diabetes patients. The study highlights the potential of AI-ECG technology to enhance heart disease detection and screening processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has received a patent grant from the Canadian Intellectual Property Office for its AI-ECG technology. The company aims to revolutionize heart disease detection, reduce treatment costs, and capitalize on the growing ECG market, with a projected value of $25 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.41%
Tags
Rhea-AI Summary
HeartSciences appoints Dr. Partho P. Sengupta, a renowned cardiologist, to its Scientific Advisory Board. Dr. Sengupta brings vast experience and expertise in AI-ECG technology, enhancing HeartSciences' position in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
Rhea-AI Summary
HeartSciences appoints Dr. Jordan B. Strom to its Scientific Advisory Board, enhancing expertise in AI-based medical devices and preparing for FDA submission of MyoVista device and cloud platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartSciences (HSCS) appoints Dr. Benjamin Glicksberg, an elite data scientist and lead investigator of AI algorithms licensed by the company, to its Scientific Advisory Board. The appointment follows the recent closing of agreements with Mount Sinai, covering an industry-leading portfolio of AI-based ECG/EKG algorithms, technologies, and patent rights for the screening and diagnosis of cardiovascular disease. The company aims to achieve significant milestones, including launching a hardware-agnostic cloud platform to deliver the AI-ECG algorithms licensed from Mount Sinai and obtaining FDA clearance for its MyoVista wavECG device. Dr. Glicksberg's expertise in machine learning, digital health, and bioinformatics is expected to contribute to expanding the clinical diagnostic capabilities of the ECG/EKG, transforming the early detection of heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) announced the results of the 2024 Annual Meeting of Shareholders, including the passing of important resolutions and an adjournment in respect of Proposal 7. Approximately 54.37% of the Company’s outstanding shares were represented at the meeting. The shareholders approved the re-election of director nominees, the issuance of shares of common stock, the Equity Incentive Plan, the independent registered public accounting firm, and amendments to the Company’s Certificate of Formation. Proposal 7, which aimed to lower the quorum for future meetings, was adjourned until February 15, 2024 due to insufficient votes. The reconvened Annual Meeting will be held virtually, and shareholders are encouraged to vote by February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
Heart Test Laboratories, Inc.
Nasdaq:HSCS
HSCS Rankings
HSCS Stock Data
6.07M
56.25M
16.01%
1.84%
0.21%
Surgical Appliance and Supplies Manufacturing
Manufacturing
United States of America
SOUTHLAKE